Skip to content

Author

J. Grant-Kels

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

The Ethical and Practical Issues of Market Exclusivity for Naturally Derived Dermatologic Medications: The Case of Cantharidin.

New dermatologic therapies derived from long-used natural substances can enter the market at prices far above previously available compounded or imported formulations, once they receive United States Food and Drug Administration (FDA) approval. Patent protection is often blamed for this shift, but the mechanism at work...

D. Khalilzadeh, Timothy Klufas, Albert E. Zhou et al. · 0 citations
Review Sep 2026

Immune Checkpoint Inhibition in Locally Advanced, Recurrent, and Metastatic Cutaneous Squamous Cell Carcinoma.

Cutaneous squamous cell carcinoma (cSCC) is a potentially aggressive non-melanoma skin cancer with rising incidence attributed to ultraviolet radiation exposure, chronic inflammation, aging, immunosuppression, and improved detection technology. Immune checkpoint inhibitors (ICIs) have transformed treatment for advanced...

A. Vromans, Bridget Harrop, Nicole Flores et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.